Unsafe
Not Aligned
Patient Risk:
Moderate
Summary
Most claims assess non-prescribing support (dose effect magnitude, discount/payment/assistance details, and pharmacy/coupon availability). None of these are supported by the provided FDA label excerpts, and one claim implies a strong triglyceride-lowering magnitude not present in the excerpts.
Category Scores
Accurate Statements
VASCEPA has an FDA-approved indication involving adjunct use to diet to reduce triglycerides in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Indications and Usage (Section 1): “as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.”
Unsupported Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglycerides in adults with severe hypertriglyceridemia.
Partially matches Section 1 but does not specify the required details (adult severe TG threshold ≥500 mg/dL and “adjunct to diet”). The claim also omits the adjunct-to-diet context.
Vascepa has been shown to reduce triglyceride levels by up to 52%.
No TG percentage magnitude (e.g., “up to 52%”) is stated in the provided label excerpts.
Amarin offers a patient assistance program that provides discounts on Vascepa auto shipments.
Patient assistance/discount program availability and terms are not described in the provided FDA label excerpts.
Patients who meet certain income and eligibility requirements may be able to receive a discount of up to 75% off the retail price through the Amarin patient assistance program.
Discount magnitude/percentage (“up to 75%”) and retail pricing are not described in the provided FDA label excerpts.
Some pharmacies (e.g., CVS Pharmacy and Walgreens) offer discounts on Vascepa auto shipments.
Pharmacy-specific discount programs are not described in the provided FDA label excerpts.
Coupon programs, such as the Vascepa Savings Card, offer discounts on Vascepa auto shipments.
Coupon/savings card program existence and terms are not described in the provided FDA label excerpts.
The Amarin Patient Assistance Program provides discounts on Vascepa auto shipments to patients who meet certain income and eligibility requirements.
Patient assistance program details are not described in the provided FDA label excerpts.
The article states that the maximum discount available for Vascepa auto shipments is up to 75% off the retail price through the Amarin Patient Assistance Program.
Label excerpts provided do not contain this information.
The cost of Vascepa without insurance can range from $250 to $300 per month, depending on the dosage and location.
Pricing/market cost ranges are not described in the provided FDA label excerpts.
Patients can apply for the Amarin Patient Assistance Program by contacting Amarin directly or by visiting their website.
Application instructions for a patient assistance program are not described in the provided FDA label excerpts.
Patients can contact Amarin by calling 1-877-4AMARIN or by visiting their website.
Contact information for patient assistance is not described in the provided FDA label excerpts.
Patients can use a coupon program in conjunction with the patient assistance program to receive additional discounts.
Terms about combining coupon and assistance programs are not described in the provided FDA label excerpts.
Contradictions
Important Omissions
For the triglyceride-lowering indication, the claim omits required labeling qualifiers (adult patients with severe TG ≥ 500 mg/dL and “adjunct to diet”).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary risk from label misalignment is informational: presenting unsupported efficacy magnitude and non-label financial access details, which may mislead patients regarding expected treatment effects and access/cost, rather than directly mis-stating contraindications, dosing, or warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Key statements are unsupported by the provided FDA label excerpts (TG reduction percentage and patient assistance/coupon/pharmacy/price details), and the triglyceride-lowering indication is incomplete versus labeled qualifiers.
Suggested Improvement
Limit claims to what is stated in the provided label excerpts (e.g., adjunct-to-diet reduction of TG in adults with severe TG ≥ 500 mg/dL; adjunct to maximally tolerated statin for CV risk reduction). Remove or re-source all patient assistance, coupon, pharmacy discount, pricing, and TG “up to 52%” statements since they are not present in the supplied labeling.